TFRC and Alzheimer disease: Bispecific antibodies that target both BACE1 and transferrin receptor achieved superior efficacy in reducing brain Aβ levels with minimal sustained toxicity in both rodent and primate AD models.[167, 190, 196] In glioblastoma, bispecific antibody targeting VEGFA and angiopep‐2 show highly effective inhibition of tumor growth through vascular and/or immunomodulatory effects.[211]